Neonatal group B streptococcal infections

Area of Science:

• Neonatal infections
• Bacterial pathogenesis
• Vaccine development

Background:

• Group B Streptococcus (GBS) is a primary cause of life-threatening neonatal infections worldwide.
• Current incidence in the US is 1.8 cases per 1000 live births, with a 10-20% fatality rate.
• Understanding GBS pathogenesis informs new treatment strategies for septic shock and meningitis.

Purpose of the Study:

• To review current and emerging strategies for preventing and treating Group B Streptococcus neonatal infections.
• To highlight the efficacy of intrapartum chemoprophylaxis and conjugate vaccines.

Main Methods:

• Review of existing literature on GBS pathogenesis, treatment, and prevention.
• Analysis of data on ampicillin chemoprophylaxis effectiveness and cost-effectiveness.
• Summary of findings from preclinical (mouse models) and early-stage human trials of GBS conjugate vaccines.

Main Results:

• Selective intrapartum chemoprophylaxis with ampicillin is effective and cost-effective, gaining acceptance.
• GBS conjugate vaccines demonstrated efficacy in preventing neonatal infection in a mouse model.
• Human trials for GBS conjugate vaccine safety and immunogenicity are underway.

Conclusions:

• Advances in understanding GBS pathogenesis are driving new therapeutic approaches.
• Ampicillin chemoprophylaxis represents a proven preventive measure.
• GBS conjugate vaccines hold significant promise for preventing neonatal infections and are progressing to human trials.